Exelixis
EXEL
#1657
Rank
S$13.73 B
Marketcap
$48.11
Share price
1.26%
Change (1 day)
68.35%
Change (1 year)
Exelixis, Inc. is an American genomics-based drug discovery company and the producer of Cometriq, a treatment for medullary thyroid cancer.

EPS for Exelixis (EXEL)

EPS in 2023 (TTM): $0.38

According to Exelixis's latest financial reports the company's current EPS (TTM) is $0.38. In 2022 the company made an earnings per share (EPS) of $0.76 a decrease over its 2021 EPS that were of $0.98.

EPS history for Exelixis from 2000 to 2023

Annual EPS

Year EPS Change
2023 (TTM)$0.38-49.47%
2022$0.76-22.97%
2021$0.98100%
2020$0.49-65.09%
2019$1.41-53.91%
2018$3.05333.96%
2017$0.70-260.61%
2016-$0.44-58.75%
2015-$1.06-42.45%
2014-$1.845.3%
2013-$1.7543.48%
2012-$1.22-264.29%
2011$0.74-165.88%
2010-$1.13-32.54%
2009-$1.67-17.65%
2008-$2.0375.86%
2007-$1.15-25.64%
2006-$1.558.33%
2005-$1.43-42.86%
2004-$2.5130.34%
2003-$1.92-5.23%
2002-$2.03-0.65%
2001-$2.04-51.88%
2000-$4.25

EPS for similar companies or competitors

Company EPS EPS differencediff. Country
$4.65 1,135.69%๐Ÿ‡ฌ๐Ÿ‡ง UK
$4.22 1,022.57%๐Ÿ‡ซ๐Ÿ‡ท France
$2.42 543.02%๐Ÿ‡บ๐Ÿ‡ธ USA
$5.27 1,301.34%๐Ÿ‡บ๐Ÿ‡ธ USA
$18.78 4,894.71%๐Ÿ‡บ๐Ÿ‡ธ USA
$18.69 4,871.87%๐Ÿ‡บ๐Ÿ‡ธ USA
$2.47 556.55%๐Ÿ‡บ๐Ÿ‡ธ USA
-$13.27-3,629.83%๐Ÿ‡บ๐Ÿ‡ธ USA
-$1.11-396.51%๐Ÿ‡บ๐Ÿ‡ธ USA